Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ning Xi

Showing results (181-190 of 195) with videos related to

Pageof 20
Sort By:
Molecular Brain|September 11, 2021
Anxiolytic effect of GABAergic neurons in the anterior cingulate cortex in a rat model of chronic inflammatory painFang-Bing Shao, Jun-Fan Fang, Si-Si Wang, et al.
Lung Cancer (Amsterdam, Netherlands)|January 5, 2024
Ningetinib plus gefitinib in EGFR-mutant non-small-cell lung cancer with MET and AXL dysregulations: A phase 1b clinical trial and biomarker analysisShen Zhao, Yuxiang Ma, Lianke Liu, et al.
ACS Sensors|July 24, 2025
Porous-Structure Flexible Muscle Sensor for Monitoring Muscle Function and MassHongyu Zhang, Keer Wang, Jiao Suo, et al.
Frontiers in Immunology|November 7, 2022
Preclinical characterization and phase I clinical trial of CT053PTSA targets MET, AXL, and VEGFR2 in patients with advanced solid tumorsYu-Xiang Ma, Fu-Rong Liu, Yang Zhang, et al.
Nature|January 10, 2024
Giant magnetocaloric effect in spin supersolid candidate Na<sub>2</sub>BaCo(PO<sub>4</sub>)<sub>2</sub>Junsen Xiang, Chuandi Zhang, Yuan Gao, et al.
Bioorganic & Medicinal Chemistry Letters|May 6, 2004
N-Aryl-gamma-lactams as integrin alphavbeta3 antagonistsNing Xi, Stephen Arvedson, Shawn Eisenberg, et al.
Journal of Medicinal Chemistry|February 11, 2012
Structure-based design of novel class II c-Met inhibitors: 2. SAR and kinase selectivity profiles of the pyrazolone seriesLongbin Liu, Mark H Norman, Matthew Lee, et al.
Journal of Medicinal Chemistry|June 9, 2006
Design of potent, orally available antagonists of the transient receptor potential vanilloid 1. Structure-activity relationships of 2-piperazin-1-yl-1H-benzimidazolesVassil I Ognyanov, Chenera Balan, Anthony W Bannon, et al.
Bioorganic & Medicinal Chemistry Letters|March 5, 2005
Melanocortin subtype-4 receptor agonists containing a piperazine core with substituted aryl sulfonamidesChristopher Fotsch, Nianhe Han, Premilla Arasasingham, et al.
Journal of Medicinal Chemistry|June 17, 2008
Discovery of a potent, selective, and orally bioavailable c-Met inhibitor: 1-(2-hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458)Longbin Liu, Aaron Siegmund, Ning Xi, et al.
Pageof 20

Showing results (181-190 of 195) with videos related to

Sort By:
Pageof 20
Molecular Brain|September 11, 2021
Anxiolytic effect of GABAergic neurons in the anterior cingulate cortex in a rat model of chronic inflammatory painFang-Bing Shao, Jun-Fan Fang, Si-Si Wang, et al.
Lung Cancer (Amsterdam, Netherlands)|January 5, 2024
Ningetinib plus gefitinib in EGFR-mutant non-small-cell lung cancer with MET and AXL dysregulations: A phase 1b clinical trial and biomarker analysisShen Zhao, Yuxiang Ma, Lianke Liu, et al.
ACS Sensors|July 24, 2025
Porous-Structure Flexible Muscle Sensor for Monitoring Muscle Function and MassHongyu Zhang, Keer Wang, Jiao Suo, et al.
Frontiers in Immunology|November 7, 2022
Preclinical characterization and phase I clinical trial of CT053PTSA targets MET, AXL, and VEGFR2 in patients with advanced solid tumorsYu-Xiang Ma, Fu-Rong Liu, Yang Zhang, et al.
Nature|January 10, 2024
Giant magnetocaloric effect in spin supersolid candidate Na<sub>2</sub>BaCo(PO<sub>4</sub>)<sub>2</sub>Junsen Xiang, Chuandi Zhang, Yuan Gao, et al.
Bioorganic & Medicinal Chemistry Letters|May 6, 2004
N-Aryl-gamma-lactams as integrin alphavbeta3 antagonistsNing Xi, Stephen Arvedson, Shawn Eisenberg, et al.
Journal of Medicinal Chemistry|February 11, 2012
Structure-based design of novel class II c-Met inhibitors: 2. SAR and kinase selectivity profiles of the pyrazolone seriesLongbin Liu, Mark H Norman, Matthew Lee, et al.
Journal of Medicinal Chemistry|June 9, 2006
Design of potent, orally available antagonists of the transient receptor potential vanilloid 1. Structure-activity relationships of 2-piperazin-1-yl-1H-benzimidazolesVassil I Ognyanov, Chenera Balan, Anthony W Bannon, et al.
Bioorganic & Medicinal Chemistry Letters|March 5, 2005
Melanocortin subtype-4 receptor agonists containing a piperazine core with substituted aryl sulfonamidesChristopher Fotsch, Nianhe Han, Premilla Arasasingham, et al.
Journal of Medicinal Chemistry|June 17, 2008
Discovery of a potent, selective, and orally bioavailable c-Met inhibitor: 1-(2-hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458)Longbin Liu, Aaron Siegmund, Ning Xi, et al.
Pageof 20